As of October 27, 2026, EyePoint is a publicly traded company (Nasdaq: EYPT); its largest reported holder is JANUS HENDERSON GROUP Ltd., with 10.9% on Schedule 13G of September 8, 2026, then Cormorant Asset Management, LP (8.35%) (Schedule 13G, September 8, 2026).
About to sign with, pay or invest in EyePoint? See the free Snapshot first.
Free to see. No signup.
Is EyePoint a real, registered company?
- EyePoint files with the SEC under CIK 1314102 (its SEC filings).
- Its shares are listed under the ticker EYPT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Watertown, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under EyePoint in our court records and SEC 8-K records (as of 2026-10-27).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-10-19).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Federated Hermes, Inc. (filed 2026-10-07).
Who are EyePoint's owners and officers?
EyePoint: incorporated in Delaware; business address in Watertown, Massachusetts; industry Laboratory Analytical Instruments (Form 8-K, 2026-10-19).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | Federated Hermes, Inc. | 8.04% |
| Schedule 13G, 2026-09-08 | Janus Henderson Group LTD. | 10.9% |
| Schedule 13G/A, 2026-08-14 | Cormorant Asset Management, LP | 8.35% |
| Schedule 13G, 2026-08-12 | Adage Capital Management, L.P. | 5.71% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.03% |
| Schedule 13G/A, 2026-07-28 | Blackrock, Inc. | 7.7% |
| Schedule 13G, 2026-06-03 | Commodore Capital LP | 5.1% |
| Schedule 13G/A, 2026-05-15 | Paradigm Biocapital Advisors LP | 3.8% |
| Schedule 13G/A, 2026-05-13 | Adage Capital Management, L.P. | 3.96% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-24 | Paradigm Biocapital Advisors LP | 5.1% |
| Schedule 13G/A, 2026-02-17 | Tcg Crossover Gp Ii, LLC | 4.3% |
Want the whole picture on EyePoint?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on EyePoint: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on EyePoint covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own EyePoint shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Cormorant Asset Management, LP: 8,265,000 shares (9.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-08).
- Bihua Chen: 8,265,000 shares (9.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-08).
- Cormorant Global Healthcare Master Fund, LP: 8,265,000 shares (9.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-08).
- , a director: 421,235 shares (0.49% of shares outstanding), 294,346 held directly and 126,889 indirectly (Form 4, 2026-01-07).
- , the chief financial officer: 219,161 shares (0.25% of shares outstanding), 129,208 held directly and 89,953 indirectly (Form 4, 2026-08-24).
Shares outstanding: 86,212,138 as of 2026-07-31, from the company's latest SEC cover page.
How much has EyePoint raised?
No fundraising or offering filing from EyePoint is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-10-19).
Keep reading
More on EyePoint and the records around it.
EyePoint elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Federated Hermes, Inc. also filed stake reports on 13 other companies: Arcturus Therapeutics Holdings Inc. (Oct 2026), aTYR PHARMA INC (Oct 2026), LifeMD (Oct 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/eyepoint